Based on the SPDR® S&P Biotech ETF stock forecast from 0 analysts, the average analyst target price for SPDR® S&P Biotech ETF is not available over the next 12 months. SPDR® S&P Biotech ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of SPDR® S&P Biotech ETF is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, SPDR® S&P Biotech ETF’s stock price was USD 82.22. SPDR® S&P Biotech ETF’s stock price has changed by -1.51% over the past week, -11.28% over the past month and +2.76% over the last year.
No recent analyst target price found for SPDR® S&P Biotech ETF
No recent average analyst rating found for SPDR® S&P Biotech ETF
Company Overview SPDR® S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI). Read Less
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the bio...Read More
Frequently Asked Questions About SPDR® S&P Biotech ETF (XBI) Stock
Stock Target Advisor's fundamental analysis for SPDR® S&P Biotech ETF's stock is Bearish.
XBI stock's dividend yield is 0.02%.
Our analysis grades XBI stock's dividend yield at F. This means that XBI stock's dividend yield is above 6% of the stocks in the Health sector in the NYE exchange.
Based on this XBI may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on XBI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on XBI's stock to indicate if its overvalued.
The last closing price of XBI's stock was USD 82.22.
The most recent market capitalization for XBI is USD 7.05B.
Unfortunately we do not have enough analyst data on XBI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains SPDR® S&P Biotech ETF's stock.
Sorry, we do not have any data on the number of employees for SPDR® S&P Biotech ETF.
Sorry we do not have any infomation available on SPDR® S&P Biotech ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XBI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
